- call +1-201-465-4211
- email sales@mrinsights.biz
Performance-enhancing drugs (PED), are substances that are used to improve any form of activity performance in humans.
Scope of the Report:
This report focuses on the Performance Enhancing Drugs in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.
A well-known example of PED involves doping in sport, where banned physical performance–enhancing drugs are used by athletes and bodybuilders. Athletic performance-enhancing substances are sometimes referred to as ergogenic aids. Cognitive performance-enhancing drugs, commonly called nootropics, are sometimes used by students to improve academic performance. Performance-enhancing substances are also used by military personnel to enhance combat performance.
The worldwide market for Performance Enhancing Drugs is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2023, from xx million US$ in 2017, according to a new GIR (Global Info Research) study.
Market Segment by Manufacturers, this report covers
Taj Pharmaceuticals
Balkan Pharmaceuticals
Bayer
AstraZeneca
Novo Nordisk
BrainAlert
Douglas Laboratories
Onnit Labs
Eli Lilly And Company
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia etc.)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
Ergogenic Aids
Nootropic
Market Segment by Applications, can be divided into
Athletes
Body Builders
Students
Militaries
There are 15 Chapters to deeply display the global Performance Enhancing Drugs market.
Chapter 1, to describe Performance Enhancing Drugs Introduction, product scope, market overview, market opportunities, market risk, market driving force;
Chapter 2, to analyze the top manufacturers of Performance Enhancing Drugs, with sales, revenue, and price of Performance Enhancing Drugs, in 2016 and 2017;
Chapter 3, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2016 and 2017;
Chapter 4, to show the global market by regions, with sales, revenue and market share of Performance Enhancing Drugs, for each region, from 2013 to 2018;
Chapter 5, 6, 7, 8 and 9, to analyze the market by countries, by type, by application and by manufacturers, with sales, revenue and market share by key countries in these regions;
Chapter 10 and 11, to show the market by type and application, with sales market share and growth rate by type, application, from 2013 to 2018;
Chapter 12, Performance Enhancing Drugs market forecast, by regions, type and application, with sales and revenue, from 2018 to 2023;
Chapter 13, 14 and 15, to describe Performance Enhancing Drugs sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
Table of Contents
1 Market Overview
1.1 Performance Enhancing Drugs Introduction
1.2 Market Analysis by Type
1.2.1 Ergogenic Aids
1.2.2 Nootropic
1.3 Market Analysis by Applications
1.3.1 Athletes
1.3.2 Body Builders
1.3.3 Students
1.3.4 Militaries
1.4 Market Analysis by Regions
1.4.1 North America (United States, Canada and Mexico)
1.4.1.1 United States Market States and Outlook (2013-2023)
1.4.1.2 Canada Market States and Outlook (2013-2023)
1.4.1.3 Mexico Market States and Outlook (2013-2023)
1.4.2 Europe (Germany, France, UK, Russia and Italy)
1.4.2.1 Germany Market States and Outlook (2013-2023)
1.4.2.2 France Market States and Outlook (2013-2023)
1.4.2.3 UK Market States and Outlook (2013-2023)
1.4.2.4 Russia Market States and Outlook (2013-2023)
1.4.2.5 Italy Market States and Outlook (2013-2023)
1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
1.4.3.1 China Market States and Outlook (2013-2023)
1.4.3.2 Japan Market States and Outlook (2013-2023)
1.4.3.3 Korea Market States and Outlook (2013-2023)
1.4.3.4 India Market States and Outlook (2013-2023)
1.4.3.5 Southeast Asia Market States and Outlook (2013-2023)
1.4.4 South America, Middle East and Africa
1.4.4.1 Brazil Market States and Outlook (2013-2023)
1.4.4.2 Egypt Market States and Outlook (2013-2023)
1.4.4.3 Saudi Arabia Market States and Outlook (2013-2023)
1.4.4.4 South Africa Market States and Outlook (2013-2023)
1.4.4.5 Nigeria Market States and Outlook (2013-2023)
1.5 Market Dynamics
1.5.1 Market Opportunities
1.5.2 Market Risk
1.5.3 Market Driving Force
2 Manufacturers Profiles
2.1 Taj Pharmaceuticals
2.1.1 Business Overview
2.1.2 Performance Enhancing Drugs Type and Applications
2.1.2.1 Product A
2.1.2.2 Product B
2.1.3 Taj Pharmaceuticals Performance Enhancing Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.2 Balkan Pharmaceuticals
2.2.1 Business Overview
2.2.2 Performance Enhancing Drugs Type and Applications
2.2.2.1 Product A
2.2.2.2 Product B
2.2.3 Balkan Pharmaceuticals Performance Enhancing Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.3 Bayer
2.3.1 Business Overview
2.3.2 Performance Enhancing Drugs Type and Applications
2.3.2.1 Product A
2.3.2.2 Product B
2.3.3 Bayer Performance Enhancing Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.4 AstraZeneca
2.4.1 Business Overview
2.4.2 Performance Enhancing Drugs Type and Applications
2.4.2.1 Product A
2.4.2.2 Product B
2.4.3 AstraZeneca Performance Enhancing Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.5 Novo Nordisk
2.5.1 Business Overview
2.5.2 Performance Enhancing Drugs Type and Applications
2.5.2.1 Product A
2.5.2.2 Product B
2.5.3 Novo Nordisk Performance Enhancing Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.6 BrainAlert
2.6.1 Business Overview
2.6.2 Performance Enhancing Drugs Type and Applications
2.6.2.1 Product A
2.6.2.2 Product B
2.6.3 BrainAlert Performance Enhancing Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.7 Douglas Laboratories
2.7.1 Business Overview
2.7.2 Performance Enhancing Drugs Type and Applications
2.7.2.1 Product A
2.7.2.2 Product B
2.7.3 Douglas Laboratories Performance Enhancing Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.8 Onnit Labs
2.8.1 Business Overview
2.8.2 Performance Enhancing Drugs Type and Applications
2.8.2.1 Product A
2.8.2.2 Product B
2.8.3 Onnit Labs Performance Enhancing Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.9 Eli Lilly And Company
2.9.1 Business Overview
2.9.2 Performance Enhancing Drugs Type and Applications
2.9.2.1 Product A
2.9.2.2 Product B
2.9.3 Eli Lilly And Company Performance Enhancing Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
3 Global Performance Enhancing Drugs Sales, Revenue, Market Share and Competition by Manufacturer (2016-2017)
3.1 Global Performance Enhancing Drugs Sales and Market Share by Manufacturer (2016-2017)
3.2 Global Performance Enhancing Drugs Revenue and Market Share by Manufacturer (2016-2017)
3.3 Market Concentration Rate
3.3.1 Top 3 Performance Enhancing Drugs Manufacturer Market Share in 2017
3.3.2 Top 6 Performance Enhancing Drugs Manufacturer Market Share in 2017
3.4 Market Competition Trend
4 Global Performance Enhancing Drugs Market Analysis by Regions
4.1 Global Performance Enhancing Drugs Sales, Revenue and Market Share by Regions
4.1.1 Global Performance Enhancing Drugs Sales and Market Share by Regions (2013-2018)
4.1.2 Global Performance Enhancing Drugs Revenue and Market Share by Regions (2013-2018)
4.2 North America Performance Enhancing Drugs Sales and Growth Rate (2013-2018)
4.3 Europe Performance Enhancing Drugs Sales and Growth Rate (2013-2018)
4.4 Asia-Pacific Performance Enhancing Drugs Sales and Growth Rate (2013-2018)
4.5 South America Performance Enhancing Drugs Sales and Growth Rate (2013-2018)
4.6 Middle East and Africa Performance Enhancing Drugs Sales and Growth Rate (2013-2018)
5 North America Performance Enhancing Drugs by Countries
5.1 North America Performance Enhancing Drugs Sales, Revenue and Market Share by Countries
5.1.1 North America Performance Enhancing Drugs Sales and Market Share by Countries (2013-2018)
5.1.2 North America Performance Enhancing Drugs Revenue and Market Share by Countries (2013-2018)
5.2 United States Performance Enhancing Drugs Sales and Growth Rate (2013-2018)
5.3 Canada Performance Enhancing Drugs Sales and Growth Rate (2013-2018)
5.4 Mexico Performance Enhancing Drugs Sales and Growth Rate (2013-2018)
6 Europe Performance Enhancing Drugs by Countries
6.1 Europe Performance Enhancing Drugs Sales, Revenue and Market Share by Countries
6.1.1 Europe Performance Enhancing Drugs Sales and Market Share by Countries (2013-2018)
6.1.2 Europe Performance Enhancing Drugs Revenue and Market Share by Countries (2013-2018)
6.2 Germany Performance Enhancing Drugs Sales and Growth Rate (2013-2018)
6.3 UK Performance Enhancing Drugs Sales and Growth Rate (2013-2018)
6.4 France Performance Enhancing Drugs Sales and Growth Rate (2013-2018)
6.5 Russia Performance Enhancing Drugs Sales and Growth Rate (2013-2018)
6.6 Italy Performance Enhancing Drugs Sales and Growth Rate (2013-2018)
7 Asia-Pacific Performance Enhancing Drugs by Countries
7.1 Asia-Pacific Performance Enhancing Drugs Sales, Revenue and Market Share by Countries
7.1.1 Asia-Pacific Performance Enhancing Drugs Sales and Market Share by Countries (2013-2018)
7.1.2 Asia-Pacific Performance Enhancing Drugs Revenue and Market Share by Countries (2013-2018)
7.2 China Performance Enhancing Drugs Sales and Growth Rate (2013-2018)
7.3 Japan Performance Enhancing Drugs Sales and Growth Rate (2013-2018)
7.4 Korea Performance Enhancing Drugs Sales and Growth Rate (2013-2018)
7.5 India Performance Enhancing Drugs Sales and Growth Rate (2013-2018)
7.6 Southeast Asia Performance Enhancing Drugs Sales and Growth Rate (2013-2018)
8 South America Performance Enhancing Drugs by Countries
8.1 South America Performance Enhancing Drugs Sales, Revenue and Market Share by Countries
8.1.1 South America Performance Enhancing Drugs Sales and Market Share by Countries (2013-2018)
8.1.2 South America Performance Enhancing Drugs Revenue and Market Share by Countries (2013-2018)
8.2 Brazil Performance Enhancing Drugs Sales and Growth Rate (2013-2018)
8.3 Argentina Performance Enhancing Drugs Sales and Growth Rate (2013-2018)
8.4 Colombia Performance Enhancing Drugs Sales and Growth Rate (2013-2018)
9 Middle East and Africa Performance Enhancing Drugs by Countries
9.1 Middle East and Africa Performance Enhancing Drugs Sales, Revenue and Market Share by Countries
9.1.1 Middle East and Africa Performance Enhancing Drugs Sales and Market Share by Countries (2013-2018)
9.1.2 Middle East and Africa Performance Enhancing Drugs Revenue and Market Share by Countries (2013-2018)
9.2 Saudi Arabia Performance Enhancing Drugs Sales and Growth Rate (2013-2018)
9.3 UAE Performance Enhancing Drugs Sales and Growth Rate (2013-2018)
9.4 Egypt Performance Enhancing Drugs Sales and Growth Rate (2013-2018)
9.5 Nigeria Performance Enhancing Drugs Sales and Growth Rate (2013-2018)
9.6 South Africa Performance Enhancing Drugs Sales and Growth Rate (2013-2018)
10 Global Performance Enhancing Drugs Market Segment by Type
10.1 Global Performance Enhancing Drugs Sales, Revenue and Market Share by Type (2013-2018)
10.1.1 Global Performance Enhancing Drugs Sales and Market Share by Type (2013-2018)
10.1.2 Global Performance Enhancing Drugs Revenue and Market Share by Type (2013-2018)
10.2 Ergogenic Aids Sales Growth and Price
10.2.1 Global Ergogenic Aids Sales Growth (2013-2018)
10.2.2 Global Ergogenic Aids Price (2013-2018)
10.3 Nootropic Sales Growth and Price
10.3.1 Global Nootropic Sales Growth (2013-2018)
10.3.2 Global Nootropic Price (2013-2018)
11 Global Performance Enhancing Drugs Market Segment by Application
11.1 Global Performance Enhancing Drugs Sales Market Share by Application (2013-2018)
11.2 Athletes Sales Growth (2013-2018)
11.3 Body Builders Sales Growth (2013-2018)
11.4 Students Sales Growth (2013-2018)
11.5 Militaries Sales Growth (2013-2018)
12 Performance Enhancing Drugs Market Forecast (2018-2023)
12.1 Global Performance Enhancing Drugs Sales, Revenue and Growth Rate (2018-2023)
12.2 Performance Enhancing Drugs Market Forecast by Regions (2018-2023)
12.2.1 North America Performance Enhancing Drugs Market Forecast (2018-2023)
12.2.2 Europe Performance Enhancing Drugs Market Forecast (2018-2023)
12.2.3 Asia-Pacific Performance Enhancing Drugs Market Forecast (2018-2023)
12.2.4 South America Performance Enhancing Drugs Market Forecast (2018-2023)
12.2.5 Middle East and Africa Performance Enhancing Drugs Market Forecast (2018-2023)
12.3 Performance Enhancing Drugs Market Forecast by Type (2018-2023)
12.3.1 Global Performance Enhancing Drugs Sales Forecast by Type (2018-2023)
12.3.2 Global Performance Enhancing Drugs Market Share Forecast by Type (2018-2023)
12.4 Performance Enhancing Drugs Market Forecast by Application (2018-2023)
12.4.1 Global Performance Enhancing Drugs Sales Forecast by Application (2018-2023)
12.4.2 Global Performance Enhancing Drugs Market Share Forecast by Application (2018-2023)
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.1.3 Marketing Channel Future Trend
13.2 Distributors, Traders and Dealers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Data Source
List of Tables and Figures
Figure Performance Enhancing Drugs Picture
Table Product Specifications of Performance Enhancing Drugs
Figure Global Sales Market Share of Performance Enhancing Drugs by Ty
ProactiveWe manage our resources 24/7 to identify issues and address them before they become problems
Quality & ReliabilityWe are committed to providing reliable and highly accurate data with an excellent quality control system
Global Outreach6 Major regions and 40+ countries level analysis accomplished
Competitive PricingOur pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery
